Lv71
4230 积分 2023-01-12 加入
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial
12天前
已关闭
HER2-directed therapy improves urothelial cancer outcomes
1个月前
已完结
Tumour-agnostic kinase inhibitors
1个月前
已完结
Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer
2个月前
已完结
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA
2个月前
已完结
[Expert consensus on combined screening for common cancers(2025 edition)]
2个月前
已完结
Exploring binding and allosteric energy landscapes for the KRAS interactions with effector proteins using Markov state modeling of conformational ensembles and allosteric network modeling
3个月前
已关闭
Taletrectinib in ROS1 Fusion–Positive Non–Small Cell Lung Cancer: Promising Yet Premature?
3个月前
已关闭
A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples Among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy In Non-Small Cell Lung Cancer
3个月前
已完结
Time‐evolved metrics for safety pharmacological assessments of small molecules and biologics
3个月前
已完结
皖公网安备34019202002308
